Lancet Respiratory Medicine最新文献

筛选
英文 中文
2025 GINA report for asthma 2025年GINA报告哮喘
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-26 DOI: 10.1016/s2213-2600(25)00242-5
Priya Venkatesan
{"title":"2025 GINA report for asthma","authors":"Priya Venkatesan","doi":"10.1016/s2213-2600(25)00242-5","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00242-5","url":null,"abstract":"","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"18 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Shyamali Dharmage: mapping lung health trajectories across the life course Shyamali损伤:绘制整个生命过程中的肺部健康轨迹
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-25 DOI: 10.1016/s2213-2600(25)00198-5
Tony Kirby
{"title":"Shyamali Dharmage: mapping lung health trajectories across the life course","authors":"Tony Kirby","doi":"10.1016/s2213-2600(25)00198-5","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00198-5","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"46 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144488357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The importance of using appropriate reference ranges in spirometry 肺活量测定中使用适当参考范围的重要性
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-24 DOI: 10.1016/s2213-2600(25)00191-2
Peter Burney, Andre Amaral, Seif Shaheen
{"title":"The importance of using appropriate reference ranges in spirometry","authors":"Peter Burney, Andre Amaral, Seif Shaheen","doi":"10.1016/s2213-2600(25)00191-2","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00191-2","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"46 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144479198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity 插管预充氧策略:仔细观察纳入标准和患者异质性
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-24 DOI: 10.1016/s2213-2600(25)00161-4
Ka Man Fong, Shek Yin Au, George Wing Yiu Ng
{"title":"Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity","authors":"Ka Man Fong, Shek Yin Au, George Wing Yiu Ng","doi":"10.1016/s2213-2600(25)00161-4","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00161-4","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"31 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144479196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial 辅助化疗治疗通过14个基因表达谱(AIM-HIGH)确定为分子高风险的IA-IIA期非鳞状非小细胞肺癌:一项国际随机3期试验
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-24 DOI: 10.1016/s2213-2600(25)00213-9
David R Spigel, Virginie Westeel, Ian C Anderson, Laurent Greillier, Florian Guisier, Olivier Bylicki, Firas B Badin, Gaelle Rousseau-Bussac, Clotilde Deldycke, Frank Griesinger, Adam Bograd, Wangjian Zhong, Jacques Le Treut, Sylvie Van Hulst, David R Gandara, Martin Reck, Petra Hoffknecht, Matthew A Gubens, John Crowley, Heiko von der Leyen, Maéva Zysman
{"title":"Adjuvant chemotherapy for stage IA–IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial","authors":"David R Spigel, Virginie Westeel, Ian C Anderson, Laurent Greillier, Florian Guisier, Olivier Bylicki, Firas B Badin, Gaelle Rousseau-Bussac, Clotilde Deldycke, Frank Griesinger, Adam Bograd, Wangjian Zhong, Jacques Le Treut, Sylvie Van Hulst, David R Gandara, Martin Reck, Petra Hoffknecht, Matthew A Gubens, John Crowley, Heiko von der Leyen, Maéva Zysman","doi":"10.1016/s2213-2600(25)00213-9","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00213-9","url":null,"abstract":"<h3>Background</h3>Survival for non-small-cell lung cancer (NSCLC) remains unacceptably low, even in stage IA–IIA. Current guidelines recommend adjuvant treatment for patients considered to be at high risk in stages IB and IIA, but suggest criteria that have not been validated to predict benefit. A previously validated, CLIA-certified 14-gene expression profile has identified patients with high-risk non-squamous NSCLC tumours in stages IA–IIA who benefitted from adjuvant chemotherapy in a non-randomised prospective study. In this prespecified interim analysis, we aimed to assess the efficacy and safety of platinum-based adjuvant chemotherapy in patients with stage IA–IIA molecular high-risk non-squamous NSCLC in a randomised trial.<h3>Methods</h3>AIM-HIGH, a randomised, phase 3 trial, was done at 45 centres in France, Germany, and the USA. Patients aged 18 years or older with stage IA–IIA non-squamous NSCLC, an adequate tumour sample, and an Eastern Cooperative Oncology Group performance status of 0–1 underwent risk stratification with the 14-gene assay. Patients with a molecular high risk, defined as those receiving a high-risk or an intermediate-risk score, were randomly assigned (1:1) to four cycles of platinum-based adjuvant chemotherapy (using local institutional standard of care regimens) or observation. Randomisation was stratified according to age, sex, and tumour size of 4 cm or more. The primary outcomes for the study and for this prespecified interim analysis were 48-month and 24-month disease-free survival, respectively, in the modified intention-to-treat (mITT) population, which was defined as randomly assigned patients who continued to meet eligibility criteria either at chemotherapy initiation or at random assignment to observation; an early interim analysis was prespecified to detect a large difference between groups. This trial is registered at <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, <span><span>NCT01817192</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span>, and is closed to enrolment.<h3>Findings</h3>Between Sept 11, 2020, and Feb 7, 2025, 449 patients were enrolled and underwent risk stratification. 236 patients with molecular high risk were randomly assigned to chemotherapy (n=124) or observation (n=112). At the time of the prespecified interim analysis, 87 patients were evaluable in the mITT population (47 [54%] males and 40 [46%] females; median age 63 years [IQR 52–74]) in the chemotherapy group and 107 (58 [54%] males and 49 [46%] females; 66 years [56–76]) in the observation group. 48 (55%) patients in the chemotherapy group and 58 (54%) patients in the observatio","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"235 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144479187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply 插管预充氧策略:更仔细地观察纳入标准和患者异质性-作者回复
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-24 DOI: 10.1016/s2213-2600(25)00189-4
Tyler Pitre, Winnie Liu, Bram Rochwerg
{"title":"Preoxygenation strategies for intubation: a closer look at inclusion criteria and patient heterogeneity – Authors' reply","authors":"Tyler Pitre, Winnie Liu, Bram Rochwerg","doi":"10.1016/s2213-2600(25)00189-4","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00189-4","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"17 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144479213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to Lancet Respir Med 2024; 12: 714–27 柳叶刀呼吸医学2024修正;12: 714 - 27所示
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-23 DOI: 10.1016/s2213-2600(25)00235-8
{"title":"Correction to Lancet Respir Med 2024; 12: 714–27","authors":"","doi":"10.1016/s2213-2600(25)00235-8","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00235-8","url":null,"abstract":"<em>Meslé MMI, Brown J, Mook P, et al. Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study.</em> Lancet Respir Med <em>2024; <strong>12:</strong> 714–27</em>—In this Article, changes have been made in the Summary (Findings section and first sentence in the Interpretation section), Research in context panel (second-to-last sentence of the Added value of this study section and last sentence of the Implications of all the available evidence section), Methods (second sentence of first paragraph and the fourth paragraph in the Data analysis section), Results (paragraphs five and seven), figure 2 heading, and Discussion (paragraph five) to clarify the definition of the boosters doses and the authors' interpretation of their differential role in saving lives. These corrections were made June 23, 2025.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"12 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144371079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxic chlorine gas cloud in Vilanova: lessons to learn 维拉诺瓦的有毒氯气云:吸取教训
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-23 DOI: 10.1016/s2213-2600(25)00196-1
Jordi Rello, Joan B Soriano
{"title":"Toxic chlorine gas cloud in Vilanova: lessons to learn","authors":"Jordi Rello, Joan B Soriano","doi":"10.1016/s2213-2600(25)00196-1","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00196-1","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"30 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144370958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated care for tuberculosis and lung health 结核病和肺部健康综合护理
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-23 DOI: 10.1016/s2213-2600(25)00195-x
Lice González-Angulo, Matteo Zignol, Dennis Falzon, Farai Mavhunga, Tereza Kasaeva
{"title":"Integrated care for tuberculosis and lung health","authors":"Lice González-Angulo, Matteo Zignol, Dennis Falzon, Farai Mavhunga, Tereza Kasaeva","doi":"10.1016/s2213-2600(25)00195-x","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00195-x","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"108 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144371077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Limertinib for EGFR mutation-positive NSCLC treatment 利莫替尼治疗EGFR突变阳性NSCLC
IF 76.2 1区 医学
Lancet Respiratory Medicine Pub Date : 2025-06-20 DOI: 10.1016/s2213-2600(25)00169-9
Yang Xia, Molly Siu Ching Li
{"title":"Limertinib for EGFR mutation-positive NSCLC treatment","authors":"Yang Xia, Molly Siu Ching Li","doi":"10.1016/s2213-2600(25)00169-9","DOIUrl":"https://doi.org/10.1016/s2213-2600(25)00169-9","url":null,"abstract":"No Abstract","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"49 1","pages":""},"PeriodicalIF":76.2,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144335161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信